Cargando…
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
BACKGROUND: Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes in patients with relapsed/refractory disease, despite the improvements in intensive standard therapy. The leukaemic cells of paediatric AML patients show high expression of the CD123 antigen, and this finding prov...
Autores principales: | Caruso, Simona, De Angelis, Biagio, Del Bufalo, Francesca, Ciccone, Roselia, Donsante, Samantha, Volpe, Gabriele, Manni, Simona, Guercio, Marika, Pezzella, Michele, Iaffaldano, Laura, Silvestris, Domenico Alessandro, Sinibaldi, Matilde, Di Cecca, Stefano, Pitisci, Angela, Velardi, Enrico, Merli, Pietro, Algeri, Mattia, Lodi, Mariachiara, Paganelli, Valeria, Serafini, Marta, Riminucci, Mara, Locatelli, Franco, Quintarelli, Concetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636687/ https://www.ncbi.nlm.nih.gov/pubmed/36335396 http://dx.doi.org/10.1186/s13045-022-01376-3 |
Ejemplares similares
-
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies
por: Guercio, Marika, et al.
Publicado: (2021) -
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
por: Quintarelli, Concetta, et al.
Publicado: (2021) -
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
por: Guercio, Marika, et al.
Publicado: (2020) -
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies
por: Manni, Simona, et al.
Publicado: (2023) -
T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies
por: Pulvirenti, Federica, et al.
Publicado: (2022)